Abiopharma

🔍 Junqueira Cristina Helena Zingaretti (Executive)

Company: Nu Holdings Ltd. (NU)

Report Date: 2026-03-23

Detailed Transactions and Holdings:

• Sold 220,000 shares of Class A ordinary shares ("Class A Shares") at $14.8151 per share (Direct)
  Date: 2026-03-23 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,977,593.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 80,000 shares of Class A Shares at $14.8105 per share (Direct)
  Date: 2026-03-23 | Code: S | equity_swap_involved: 0 | shares_owned_after: 2,312,338.00 | transaction_form_type: 4 | Footnotes: F3, F2
• Holds 0 shares of Class A Shares (Direct)
  Date: 2026-03-23 | Code: H | nature_of_ownership: By Family Trust | shares_owned_after: 490,899.00 | Footnotes: F2
• Holds 0 shares of Class A Shares (Direct)
  Date: 2026-03-23 | Code: H | nature_of_ownership: By Estate Planning Vehicle | shares_owned_after: 1,539,000.00 | Footnotes: F2
• Holds 0 shares of Class A Shares (Direct)
  Date: 2026-03-23 | Code: H | shares_owned_after: 2,623,395.00 | Footnotes: F4

Footnotes:

• F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.8100 to $14.8300, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
• F2: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.8101 to $14.8150, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
• F4: Figure includes 1,285,395 Class A Ordinary Shares underlying unvested Restricted Share Units (RSUs) associated with prior grant(s). Each RSU represents a contingent right to receive one Class A Ordinary share. These RSUs are subject to the Reporting Person's continued service through the vesting date.